Emerging viral diseases and infectious disease risks

New pathogens and antimicrobial-resistant forms of older pathogens continue to emerge, some with the potential for rapid, global spread and high morbidity and mortality. Pathogens can emerge either through introduction into a new population or when the interaction with the vector changes; emergence is also influenced by microbiological adaptation and change, global travel patterns, domestic […]


It is important that hemophilia treatment centres, in close collaboration with patient organizations, take action to inform people with bleeding disorders about the COVID-19 vaccines and contribute to an effective vaccination program. People with bleeding disorders are not at greater risk of contracting COVID-19 or developing a severe form of the disease, so they are […]

Epidemiological characteristics of human prion diseases

In the absence of specific therapies for human prion diseases, which are frequently associated with neurodegenerative disorders with fatal outcome, only an active surveillance can be used to monitor and prevent the transmission of such diseases. For this reason, starting from 1993, surveillance systems have been established in many countries. Moreover, there is urgent need […]

Detection and analysis of blood donors seropositive for syphilis

Background:The increasing incidence of syphilis worldwide has called attention to the risk of transmission by transfusion. Aims:To determine the prevalence of active syphilis in blood donors and characterise the serological profile of syphilis-positive donors. Methods: Samples positive for Treponema pallidum using the chemiluminescent microparticle immunoassay (CMIA) during blood donor screening from 2017 to 2018 were tested by […]

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients’ quality of life. The half-life of recombinant factor VIII ranges from 15 to 19 hours because of the von Willebrand factor chaperone effect. BIVV001 (rFVIIIFc-VWF-XTEN) is a novel fusion protein designed to […]